Remus Pharmaceuticals Share PriceRemus Pharmaceuticals

₹4935.05
131.1 (2.73%)
As on 27 September, 2023 | 01:11 BSE: NSE: REMUSISIN: INE0O5T01011

Remus Pharmaceuticals Performance

Day Range

  • Low 4815
  • High 5041.95
4935.05

52 Week Range

  • Low 1711.25
  • High 5041.95
4935.05
  • Open Price4890
  • Previous Close4803.95
  • Volume10500

Start SIP in Remus Pharmaceuticals

Start SIP

Remus Pharmaceuticals Share Price

  • Over 1 Month 9.26%
  • Over 3 Month 64.4%

Remus Pharmaceuticals Key Statistics

P/E Ratio
PEG Ratio
Market Cap Cr 727
Price to Book Ratio 38
EPS 57.7
Dividend 0
Relative Strength Index 69.83
Money Flow Index 76.97
MACD Signal 66.01
Average True Range 200.46

Remus Pharmaceuticals Investment Rating

  • Master Rating:
  • Remus Pharmaceuticals Ltd has an operating revenue of Rs. 100.08 Cr. on a trailing 12-month basis. An annual revenue growth of 83% is outstanding, Pre-tax margin of 25% is great, ROE of 44% is exceptional. The company has a reasonable debt to equity of 37%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 28% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 0% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 77 which is a FAIR score but needs to improve its earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 18 indicates it belongs to a strong industry group of Medical-Whlsle Drg/Suppl and a Master Score of A is the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Remus Pharmaceuticals Financials
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 4725
Operating Expenses Annual Cr 3421
Operating Profit Annual in Cr 114
Depreciation Cr 00
Interest Annual Cr 00
Tax Annual Cr 31
Net Profit Annual Cr 93
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 55
Cash from Investing Activity Annual Cr -15-5
Cash from Financing Annual Activity Cr 120
Net Cash Flow Annual Cr 20
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 196
Fixed Assets Annual Cr 30
Total Non Current Assets Annual Cr 238
Total Current Assets Annual Cr 118
Total Assets Annual Cr 3516
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 17664
ROE Annual % 4453
ROCE Annual % 4469
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2719
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr
Operating Expenses Annual Cr
Operating Profit Annual in Cr
Depreciation Cr
Interest Annual Cr
Tax Annual Cr
Net Profit Annual Cr
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr
Net Cash Flow Annual Cr
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr
Fixed Assets Annual Cr
Total Non Current Assets Annual Cr
Total Current Assets Annual Cr
Total Assets Annual Cr
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs
ROE Annual %
ROCE Annual %
Total Debt to Total Equity Annual --
EBDIT Annual Margin %

Remus Pharmaceuticals Technicals

EMA & SMA

Current Price
₹4935.05
131.1 (2.73%)
  • Bullish Moving Average
  • ___
  • 11
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹4440.49
  • 50 Day
  • ₹4123.98
  • 100 Day
  • 200 Day
  • 20 Day
  • ₹4369.8
  • 50 Day
  • ₹4238.65
  • 100 Day
  • 200 Day

Remus Pharmaceuticals Resistance and Support

PIVOT
₹4930.67
Resistance
First Resistance ₹5046.34
Second Resistance ₹5157.62
Third Resistance ₹5273.29
RSI 69.83
MFI 76.97
MACD Single Line 66.02
MACD 118.98
Support
First Resistance ₹4819.39
Second Resistance ₹4703.72
Third Resistance ₹4592.44

Remus Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 10,500 929,985 88.57
Week 6,740 576,000 85.46
1 Month 3,838 304,745 79.4
6 Month 6,008 496,332 82.61

Remus Pharmaceuticals Result Highlights

Remus Pharmaceuticals Synopsis

NSE-Medical-Whlsle Drg/Suppl

Remus Pharmaceutic belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 45.03 Cr. and Equity Capital is Rs. 1.09 Cr. for the Year ended 31/03/2023. Remus Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24232GJ2015PLC084536 and registration number is 084536.
Market Cap 727
Sales 45
Shares in Float 0.05
No of funds 19
Yield
Book Value 27.98
U/D Vol ratio 1.6
LTDebt / Equity 37
Alpha 1.13
Beta 1.61

Remus Pharmaceuticals

Owner NameMay-23
Promoters 68.37%
Foreign Portfolio Investors 2.55%
Financial Institutions/ Banks 0.92%
Individual Investors 16.69%
Others 11.47%

Remus Pharmaceuticals Management

Name Designation
Mr. Swapnil Jatinbhai Shah Chairman & Wholetime Director
Mr. Arpit Deepakkumar Shah Managing Director
Mrs. Anar Swapnil Shah Whole Time Director
Ms. Roma Vinodbhai Shah Whole Time Director
Mr. Balwant Purohit Independent Director
Mrs. Sanjana Sanjeev Shah Independent Director
Mr. Vishrut Chandramauli Pathak Independent Director

Remus Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

  • Company Name
  • CMP
  • Chg(%)
  • Company Name
  • CMP
  • Chg(%)

Remus Pharmaceuticals FAQs

What is Share Price of Remus Pharmaceuticals ?

Remus Pharmaceuticals share price is ₹4935 As on 27 September, 2023 | 00:57

What is the Market Cap of Remus Pharmaceuticals ?

The Market Cap of Remus Pharmaceuticals is ₹726.9 Cr As on 27 September, 2023 | 00:57

What is the P/E ratio of Remus Pharmaceuticals ?

The P/E ratio of Remus Pharmaceuticals is As on 27 September, 2023 | 00:57

What is the PB ratio of Remus Pharmaceuticals ?

The PB ratio of Remus Pharmaceuticals is 38 As on 27 September, 2023 | 00:57

Q2FY23